{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:22:07Z","timestamp":1792077727144,"version":"4.4.0"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cca.2025.120586","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T06:44:47Z","timestamp":1756881887000},"page":"120586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Residual disease in NPM1-mutated acute myeloid leukemia"],"prefix":"10.1016","volume":"579","author":[{"given":"Pejman","family":"Hamedi-Asl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amineh","family":"Hosseinkhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafiseh","family":"Sanei-Ataabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Ranjbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horsa Sadat","family":"Seyedebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taraneh","family":"Hoseinnezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paria","family":"Zahedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davod","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Safa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.cca.2025.120586_b0005","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.cca.2025.120586_b0010","unstructured":"Khoury, J.D., et al., The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. leukemia, 20236(7): p. 1703-1719."},{"issue":"5","key":"10.1016\/j.cca.2025.120586_b0015","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.leu.2404637","article-title":"Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations","volume":"21","author":"Chou","year":"2007","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.cca.2025.120586_b0020","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/ajh.21879","article-title":"Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient\u2010specific NPM1 mutations","volume":"85","author":"Dvorakova","year":"2010","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.cca.2025.120586_b0025","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2404149","article-title":"Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations","volume":"20","author":"Gorello","year":"2006","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.cca.2025.120586_b0030","doi-asserted-by":"crossref","first-page":"994","DOI":"10.5858\/2010-0490-OAR1","article-title":"Detection of nucleophosmin 1 mutations by quantitative real-time polymerase chain reaction versus capillary electrophoresis: a comparative study","volume":"135","author":"Barakat","year":"2011","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"10","key":"10.1016\/j.cca.2025.120586_b0035","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","article-title":"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)","volume":"107","author":"Thiede","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cca.2025.120586_b0040","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.cca.2025.120586_b0045","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood.2020005998","article-title":"Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial","volume":"136","author":"Kapp-Schwoerer","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cca.2025.120586_b0050","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/gcc.22375","article-title":"Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia","volume":"55","author":"Pettersson","year":"2016","journal-title":"Genes Chromosom. Cancer"},{"issue":"12","key":"10.1016\/j.cca.2025.120586_b0055","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.cca.2025.120586_b0060","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.cca.2025.120586_b0065","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166268","article-title":"GPX1-associated prognostic signature predicts poor survival in patients with acute myeloid leukemia and involves in immunosuppression","volume":"1868","author":"Zhang","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"issue":"4","key":"10.1016\/j.cca.2025.120586_b0520","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijlh.13608","article-title":"Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia","volume":"43","author":"Pettersson","year":"2021","journal-title":"Int. J. Lab. Hematol."},{"issue":"4","key":"10.1016\/j.cca.2025.120586_b0265","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jmoldx.2017.03.005","article-title":"Minimal residual disease monitoring of acute myeloid leukemia by massively multiplex digital PCR in patients with NPM1 mutations","volume":"19","author":"Mencia-Trinchant","year":"2017","journal-title":"J. Mol. Diagn."},{"issue":"6","key":"10.1016\/j.cca.2025.120586_b0525","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.3390\/curroncol30060395","article-title":"Novel tools for diagnosis and monitoring of AML","volume":"30","author":"Guijarro","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.cca.2025.120586_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2020.101617","article-title":"Development and validation of a droplet digital PCR assay for the evaluation of PML-RAR\u03b1 fusion transcripts in acute promyelocytic leukemia","volume":"53","author":"Jiang","year":"2020","journal-title":"Mol. Cell. Probes"},{"issue":"10","key":"10.1016\/j.cca.2025.120586_b0350","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa2024534","article-title":"Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers","volume":"384","author":"Duncavage","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cca.2025.120586_b0535","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s12185-024-03841-w","article-title":"Comparison of disease and risk classifications of AML before and after incorporation of NGS analysis of bone marrow samples","volume":"120","author":"Sugiura","year":"2024","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0540","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13046-023-02841-8","article-title":"Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment","volume":"42","author":"Peroni","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"Suppl 3","key":"10.1016\/j.cca.2025.120586_b0545","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00292-023-01268-4","article-title":"NGS-based molecular genetics of leukemia-a powerful and decentralized approach","volume":"44","author":"Dintner","year":"2023","journal-title":"Pathologie (Heidelb)"},{"issue":"8","key":"10.1016\/j.cca.2025.120586_b0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e29382","article-title":"CRISPR screens in mechanism and target discovery for AML","volume":"10","author":"Lin","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0555","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.stem.2022.12.006","article-title":"METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism","volume":"30","author":"Han","year":"2023","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.cca.2025.120586_b0560","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1158\/2159-8290.CD-20-1851","article-title":"An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML","volume":"12","author":"Lin","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0565","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s12967-022-03765-1","article-title":"Integration of CRISPR\/Cas9 with artificial intelligence for improved cancer therapeutics","volume":"20","author":"Bhat","year":"2022","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0295","doi-asserted-by":"crossref","first-page":"7244","DOI":"10.1038\/s41467-021-27472-5","article-title":"Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia","volume":"12","author":"Benard","year":"2021","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.cca.2025.120586_b0570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004462","article-title":"Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing","volume":"10","author":"Hughes","year":"2014","journal-title":"PLoS Genet."},{"issue":"2","key":"10.1016\/j.cca.2025.120586_b0575","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2018.203133","article-title":"Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia","volume":"104","author":"Dillon","year":"2018","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.cca.2025.120586_b0080","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMra2302038","article-title":"Artificial intelligence and machine learning in clinical medicine, 2023","volume":"388","author":"Haug","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0580","doi-asserted-by":"crossref","first-page":"17874","DOI":"10.1038\/s41598-024-68755-3","article-title":"Machine learning-based biomarker screening for acute myeloid leukemia prognosis and therapy from diverse cell-death patterns","volume":"14","author":"Qin","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0585","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00716-5","article-title":"Unlocking the potential of artificial intelligence in acute myeloid leukemia and myelodysplastic syndromes","volume":"19","author":"Alhajahjeh","year":"2024","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"19","key":"10.1016\/j.cca.2025.120586_b0590","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood.2021012455","article-title":"Machine learning finds new AML subtypes","volume":"138","author":"Thomas","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cca.2025.120586_b0595","unstructured":"Lin, M., et al., Application of deep learning on predicting prognosis of acute myeloid leukemia with cytogenetics, age, and mutations. arXiv preprint arXiv:1810.13247, 2018."},{"issue":"2","key":"10.1016\/j.cca.2025.120586_b0070","first-page":"127","article-title":"Artificial intelligence in cancer imaging: clinical challenges and applications","volume":"69","author":"Bi","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"26","key":"10.1016\/j.cca.2025.120586_b0075","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMra2204787","article-title":"Artificial intelligence in molecular medicine","volume":"388","author":"Gomes","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.cca.2025.120586_b0085","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMra2214183","article-title":"Medical artificial intelligence and human values","volume":"390","author":"Yu","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.cca.2025.120586_b0090","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMra2212850","article-title":"Where medical statistics meets artificial intelligence","volume":"389","author":"Hunter","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.cca.2025.120586_b0095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-019-0244-2","article-title":"A novel machine-learning-derived genetic score correlates with measurable residual disease and is highly predictive of outcome in acute myeloid leukemia with mutated NPM1","volume":"9","author":"Patkar","year":"2019","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0100","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/bjh.16857","article-title":"Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease","volume":"191","author":"Bataller","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.cca.2025.120586_b0105","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1600-0609.2011.01673.x","article-title":"NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression","volume":"87","author":"Kristensen","year":"2011","journal-title":"Eur. J. Haematol."},{"issue":"23","key":"10.1016\/j.cca.2025.120586_b0110","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood-2014-05-577593","article-title":"Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for \u201cprime time\u201d?","volume":"124","author":"Grimwade","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cca.2025.120586_b0115","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.cca.2025.120586_b0120","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-021-01230-4","article-title":"Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations","volume":"35","author":"Walter","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0125","doi-asserted-by":"crossref","first-page":"17695","DOI":"10.1038\/s41598-020-73782-x","article-title":"Preferential transcription of the mutated allele in NPM1 mutated acute myeloid leukaemia","volume":"10","author":"Bailey","year":"2020","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.cca.2025.120586_b0130","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41379-020-0498-z","article-title":"Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment","volume":"33","author":"Patel","year":"2020","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.cca.2025.120586_b0135","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.cca.2025.120586_b0140","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.2019004226","article-title":"NPM1-mutated acute myeloid leukemia: from bench to bedside","volume":"136","author":"Falini","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0145","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000530253","article-title":"NPM1-mutated acute myeloid leukemia: recent developments and open questions","volume":"91","author":"Patel","year":"2024","journal-title":"Pathobiology"},{"issue":"11","key":"10.1016\/j.cca.2025.120586_b0150","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1038\/s41375-021-01222-4","article-title":"Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field","volume":"35","author":"Falini","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.cca.2025.120586_b0155","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2006-07-012252","article-title":"Acute myeloid leukemia carrying cytoplasmic\/mutated nucleophosmin (NPMc+ AML): biologic and clinical features","volume":"109","author":"Falini","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.cca.2025.120586_b0165","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2009-01-197871","article-title":"AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features","volume":"114","author":"Haferlach","year":"2009","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.cca.2025.120586_b0170","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood.2019001240","article-title":"Molecular roulette: nucleophosmin mutations in AML are orchestrated through N-nucleotide addition by TdT","volume":"134","author":"Borrow","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cca.2025.120586_b0175","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41375-021-01498-6","article-title":"\u201cBlasts\u201d in myeloid neoplasms\u2013how do we define blasts and how do we incorporate them into diagnostic schema moving forward?","volume":"36","author":"Chen","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.cca.2025.120586_b0180","first-page":"2300","article-title":"The mechanism of induction of complete remission in acute myeloblastic leukemia in man","volume":"29","author":"Hart","year":"1969","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.cca.2025.120586_b0185","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/leu.2013.318","article-title":"What does MRD in leukemia really mean?","volume":"28","author":"Goldman","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.cca.2025.120586_b0190","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16116","article-title":"Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD\u2010driven salvage approach","volume":"186","author":"Guolo","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.cca.2025.120586_b0195","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijlh.13608","article-title":"Comparison of RNA\u2010and DNA\u2010based methods for measurable residual disease analysis in NPM1\u2010mutated acute myeloid leukemia","volume":"43","author":"Pettersson","year":"2021","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.cca.2025.120586_b0200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00277-019-03861-1","article-title":"The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia","volume":"99","author":"Gao","year":"2020","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0205","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","article-title":"The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML","volume":"122","author":"Shayegi","year":"2013","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.cca.2025.120586_b0210","doi-asserted-by":"crossref","first-page":"7912","DOI":"10.3390\/ijms25147912","article-title":"Evaluation of a new closed-system automated RT-qPCR assay for the rapid detection and monitoring of common nucleophosmin mutations in patients with acute myeloid leukemia","volume":"25","author":"Press","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"45","key":"10.1016\/j.cca.2025.120586_b0215","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1038\/sj.onc.1208832","article-title":"Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimens","volume":"24","author":"Dominguez","year":"2005","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0220","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1038\/s41598-023-31871-7","article-title":"LNA blockers for improved amplification selectivity","volume":"13","author":"Prout","year":"2023","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.cca.2025.120586_b0225","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/jcla.21779","article-title":"Mutant enrichment with 3\u2032\u2010modified oligonucleotides (MEMO)\u2010quantitative PCR for detection of NPM1 mutations in acute myeloid leukemia","volume":"29","author":"Shin","year":"2015","journal-title":"J. Clin. Lab. Anal."},{"issue":"9","key":"10.1016\/j.cca.2025.120586_b0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274034","article-title":"Development of E-ice-COLD-PCR assay combined with HRM analysis for Nucleophosmin1 gene mutation detection in acute myelogenous leukemia","volume":"17","author":"Kongta","year":"2022","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.cca.2025.120586_b0235","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jmoldx.2011.07.003","article-title":"Mutant enrichment with 3\u2032-modified oligonucleotides: a practical PCR method for detecting trace mutant DNAs","volume":"13","author":"Lee","year":"2011","journal-title":"J. Mol. Diagn."},{"issue":"10","key":"10.1016\/j.cca.2025.120586_b0240","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/sj.leu.2404367","article-title":"Rapid and sensitive typing of NPM1 mutations using LNA-mediated PCR clamping","volume":"20","author":"Thiede","year":"2006","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.cca.2025.120586_b0245","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1002\/jmv.25724","article-title":"Detection of TERT promoter mutation in serum cell\u2010free DNA using wild\u2010type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma","volume":"92","author":"Akuta","year":"2020","journal-title":"J. Med. Virol."},{"issue":"4","key":"10.1016\/j.cca.2025.120586_b0250","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jmoldx.2017.04.008","article-title":"NPM1 for MRD? Droplet like it's hot!","volume":"19","author":"Wertheim","year":"2017","journal-title":"J. Mol. Diagn."},{"issue":"10","key":"10.1016\/j.cca.2025.120586_b0255","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/nmeth.2633","article-title":"Absolute quantification by droplet digital PCR versus analog real-time PCR","volume":"10","author":"Hindson","year":"2013","journal-title":"Nat. Methods"},{"issue":"5","key":"10.1016\/j.cca.2025.120586_b0260","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.13038","article-title":"Quantification of rare NPM1 mutation subtypes by digital PCR","volume":"167","author":"Bacher","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.cca.2025.120586_b0270","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s12185-022-03402-z","article-title":"Droplet digital PCR for genetic mutations monitoring predicts relapse risk in pediatric acute myeloid leukemia","volume":"116","author":"Chen","year":"2022","journal-title":"Int. J. Hematol."},{"issue":"8","key":"10.1016\/j.cca.2025.120586_b0275","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jmoldx.2021.05.001","article-title":"Double drop-off droplet digital pcr: a novel, versatile tool for mutation screening and residual disease monitoring in acute myeloid leukemia using cellular or cell-free DNA","volume":"23","author":"Rausch","year":"2021","journal-title":"J. Mol. Diagn."},{"issue":"10","key":"10.1016\/j.cca.2025.120586_b0280","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00277-018-3373-y","article-title":"Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients","volume":"97","author":"Bill","year":"2018","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0285","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1038\/s41598-024-57016-y","article-title":"Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies","volume":"14","author":"Ip","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0290","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12967-024-05114-w","article-title":"Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML\/MDS: a multicenter retrospective study","volume":"22","author":"Chen","year":"2024","journal-title":"J. Transl. Med."},{"issue":"5","key":"10.1016\/j.cca.2025.120586_b0300","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrg.2017.117","article-title":"Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations","volume":"19","author":"Salk","year":"2018","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0305","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12308-020-00440-6","article-title":"Molecular methods for measurable residual disease in acute myeloid leukemia: where are we and where are we going?","volume":"14","author":"Carlsen","year":"2021","journal-title":"J. Hematop."},{"issue":"5","key":"10.1016\/j.cca.2025.120586_b0310","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/bloodadvances.2024014490","article-title":"Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML","volume":"9","author":"Vonk","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.cca.2025.120586_b0315","first-page":"1","article-title":"The correlation of next-generation sequencing-based genotypic profiles with clinicopathologic characteristics in NPM1-mutated acute myeloid leukemia","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Cancer"},{"issue":"16","key":"10.1016\/j.cca.2025.120586_b0320","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol","year":"2018","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.cca.2025.120586_b0325","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/bloodadvances.2020002306","article-title":"Mutational analysis of hematologic neoplasms in 164 paired peripheral blood and bone marrow samples by next-generation sequencing","volume":"4","author":"Lucas","year":"2020","journal-title":"Blood Adv."},{"issue":"22","key":"10.1016\/j.cca.2025.120586_b0330","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/bloodadvances.2018023432","article-title":"NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse","volume":"2","author":"H\u00f6llein","year":"2018","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.cca.2025.120586_b0335","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/10428194.2018.1485910","article-title":"Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML","volume":"60","author":"Delsing Malmberg","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"93","key":"10.1016\/j.cca.2025.120586_b0340","doi-asserted-by":"crossref","first-page":"36613","DOI":"10.18632\/oncotarget.26400","article-title":"Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia","volume":"9","author":"Patkar","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.cca.2025.120586_b0345","doi-asserted-by":"crossref","first-page":"617","DOI":"10.18632\/oncotarget.26610","article-title":"Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia","volume":"10","author":"Patkar","year":"2019","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.cca.2025.120586_b0355","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nrg.2016.49","article-title":"Coming of age: ten years of next-generation sequencing technologies","volume":"17","author":"Goodwin","year":"2016","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0360","doi-asserted-by":"crossref","first-page":"10950","DOI":"10.1038\/s41598-018-29325-6","article-title":"Systematic evaluation of error rates and causes in short samples in next-generation sequencing","volume":"8","author":"Pfeiffer","year":"2018","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.cca.2025.120586_b0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224097","article-title":"Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing","volume":"14","author":"Balagopal","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2025.120586_b0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12864-018-4703-0","article-title":"Characterization and remediation of sample index swaps by non-redundant dual indexing on massively parallel sequencing platforms","volume":"19","author":"Costello","year":"2018","journal-title":"BMC Genomics"},{"issue":"5","key":"10.1016\/j.cca.2025.120586_b0375","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41375-021-01131-6","article-title":"Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)","volume":"35","author":"Patkar","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.cca.2025.120586_b0380","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood.2019002959","article-title":"Molecular MRD status and outcome after transplantation in NPM1-mutated AML","volume":"135","author":"Dillon","year":"2020","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.cca.2025.120586_b0385","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","article-title":"Next-generation sequencing\u2013based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0390","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0395","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1186\/s12967-024-05570-4","article-title":"Harnessing the evolving CRISPR\/Cas9 for precision oncology","volume":"22","author":"Li","year":"2024","journal-title":"J. Transl. Med."},{"issue":"10","key":"10.1016\/j.cca.2025.120586_b0400","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1182\/bloodadvances.2022008966","article-title":"Applying CRISPR-Cas9 screens to dissect hematological malignancies","volume":"7","author":"Iyer","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.cca.2025.120586_b0405","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1182\/blood-2023-182679","article-title":"One-Pot Era-CRISPR\/Cas12a system for rapid and sensitive detection of multiple NPM1 mutations","volume":"142","author":"Liu","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0410","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1038\/s41467-024-49414-7","article-title":"CoHIT: a one-pot ultrasensitive ERA-CRISPR system for detecting multiple same-site indels","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"issue":"6387","key":"10.1016\/j.cca.2025.120586_b0415","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1126\/science.aaq0179","article-title":"Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6","volume":"360","author":"Gootenberg","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.cca.2025.120586_b0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-021-01456-x","article-title":"EasyCatch, a convenient, sensitive and specific CRISPR detection system for cancer gene mutations","volume":"20","author":"Liu","year":"2021","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.cca.2025.120586_b0425","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41551-023-01072-8","article-title":"Detection of low-frequency mutations in clinical samples by increasing mutation abundance via the excision of wild-type sequences","volume":"7","author":"Chen","year":"2023","journal-title":"Nat. Biomed. Eng."},{"issue":"01","key":"10.1016\/j.cca.2025.120586_b0430","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/BS9.0000000000000015","article-title":"Tumor heterogeneity of acute myeloid leukemia: Insights from single-cell sequencing","volume":"1","author":"Chen","year":"2019","journal-title":"Blood Sci."},{"issue":"9","key":"10.1016\/j.cca.2025.120586_b0435","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1101\/gr.232272.117","article-title":"High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics","volume":"28","author":"Pellegrino","year":"2018","journal-title":"Genome Res."},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0440","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/biomedicines12010066","article-title":"Single-cell DNA sequencing and immunophenotypic profiling to track clonal evolution in an acute myeloid leukemia patient","volume":"12","author":"Garc\u00eda-\u00c1lvarez","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0445","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/s41467-019-09745-2","article-title":"Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation","volume":"10","author":"Cocciardi","year":"2019","journal-title":"Nat. Commun."},{"issue":"7834","key":"10.1016\/j.cca.2025.120586_b0450","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.cca.2025.120586_b0455","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood.2019004770","article-title":"Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia","volume":"135","author":"Hasserjian","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cca.2025.120586_b0460","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/bloodadvances.2019001181","article-title":"Single-cell mutational profiling enhances the clinical evaluation of AML MRD","volume":"4","author":"Ediriwickrema","year":"2020","journal-title":"Blood Adv."},{"issue":"38","key":"10.1016\/j.cca.2025.120586_b0465","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg0488","article-title":"Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia","volume":"9","author":"Robinson","year":"2023","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.cca.2025.120586_b0470","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3324\/haematol.2018.194712","article-title":"A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia","volume":"104","author":"Onecha","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2025.120586_b0475","unstructured":"Nazha, A. Artificial Intelligence in Hematology, Current Challenges and Opportunities. in 2021 TCT| Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. 2021. Tandem Meetings."},{"key":"10.1016\/j.cca.2025.120586_b0480","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025029876","article-title":"Artificial Intelligence in Hematology","author":"Nazha","year":"2025","journal-title":"Blood J."},{"key":"10.1016\/j.cca.2025.120586_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100914","article-title":"The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence","volume":"54","author":"Passamonti","year":"2022","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0490","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41375-021-01408-w","article-title":"Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears","volume":"36","author":"Eckardt","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cca.2025.120586_b0495","doi-asserted-by":"crossref","first-page":"23780","DOI":"10.1038\/s41598-024-75168-9","article-title":"Integrating holotomography and deep learning for rapid detection of NPM1 mutations in AML","volume":"14","author":"Kim","year":"2024","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.cca.2025.120586_b0500","doi-asserted-by":"crossref","first-page":"7997","DOI":"10.1007\/s00432-023-04667-5","article-title":"An overview and a roadmap for artificial intelligence in hematology and oncology","volume":"149","author":"R\u00f6sler","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.cca.2025.120586_b0505","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1097\/01.HS9.0000850052.30084.5a","article-title":"PB1800: deepdecon: a deep-learning method for detecting minimal residual disease of acute myeloid leukemia","volume":"6","author":"Zhong","year":"2022","journal-title":"HemaSphere"},{"issue":"9","key":"10.1016\/j.cca.2025.120586_b0510","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1056\/NEJMra2214964","article-title":"Considering biased data as informative artifacts in AI-assisted health care","volume":"389","author":"Ferryman","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125004656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125004656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:35:36Z","timestamp":1766511336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898125004656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":119,"alternative-id":["S0009898125004656"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2025.120586","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Residual disease in NPM1-mutated acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2025.120586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120586"}}